You notice more scalp showing through your hair, or a patch that was not there last month. The instinct is to search "am I going bald?" But not all hair loss follows the same script. Alopecia areata and androgenetic alopecia are two fundamentally different conditions with different causes, different patterns, and completely different treatments. Confusing the two can cost you months of ineffective treatment. This guide breaks down the clinical distinctions so you can have a more productive conversation with your dermatologist. BaldingAI's zone-based tracking captures the visual evidence that helps clinicians differentiate between the two.
TL;DR
- Alopecia areata (AA) is autoimmune: T-cells attack healthy follicles, creating smooth round patches.
- Androgenetic alopecia (AGA) is hormonal: DHT miniaturizes follicles in predictable patterns over years.
- AA affects about 2% of the population. AGA affects 50% of men by age 50 and 40% of women by menopause.
- AA has a 50% chance of spontaneous regrowth within one year. AGA is progressive without treatment.
- Getting the diagnosis right is critical because the treatment protocols have zero overlap.
Important
This article is educational and not medical advice. If you are worried about sudden shedding, scalp symptoms, or side effects, talk to a licensed clinician.
Alopecia areata: an immune system misfire
Alopecia areata is a chronic autoimmune condition. The immune system mistakenly identifies hair follicles as foreign invaders and sends T-lymphocytes to attack them. This creates a distinctive pattern: smooth, round or oval patches of complete hair loss, often appearing suddenly. The affected skin looks normal (no scarring, no scaling), but the hair is simply gone.
According to the National Alopecia Areata Foundation, AA affects roughly 2% of the global population at some point in their lives. It can strike at any age, though most cases begin before age 30. There is a genetic component (about 10-20% of people with AA have a family member with the condition), and it is associated with other autoimmune diseases like thyroid disorders, vitiligo, and type 1 diabetes.
One hallmark feature of AA is "exclamation mark hairs," short broken hairs that taper at the base and are thicker at the top. Dermatologists look for these at the edges of bald patches as a diagnostic clue. If you see them, that is a strong signal that the loss is autoimmune rather than hormonal.
Androgenetic alopecia: hormones and genetics
Androgenetic alopecia is the medical term for pattern hair loss, the type most people mean when they say "going bald." It is driven by dihydrotestosterone (DHT), an androgen hormone that binds to receptors in genetically sensitive follicles and gradually shrinks them. Each growth cycle produces a thinner, shorter hair until the follicle eventually produces only fine vellus fuzz.
In men, AGA follows the Norwood scale: recession at the temples, thinning at the crown, and eventual convergence into broad-area baldness. In women, it typically presents as diffuse thinning along the part line, classified by the Ludwig scale. The prevalence is staggering: 50% of men show visible signs by age 50, and roughly 40% of women experience noticeable thinning by menopause.
Unlike AA, AGA does not create smooth bald patches. The hair does not vanish overnight. Instead, follicle miniaturization unfolds over months and years, with the affected area becoming progressively thinner. The scalp may become more visible through the hair, but the skin itself looks normal.
Side-by-side: how to tell them apart
The visual differences between AA and AGA are distinct once you know what to look for. AA produces round or oval smooth patches that can appear anywhere on the scalp (or body). The edges are well-defined, and exclamation mark hairs are often visible at the margins. Loss can happen within days or weeks.
AGA follows predictable patterns. In men, it starts at the hairline and crown. In women, it centers on the part line and top of the scalp. The transition is gradual, not patchy. You will not wake up with a new bare spot. Instead, you will notice the hair becoming finer and the scalp becoming more visible over a period of months. This gradual nature is actually what makes AGA harder to detect early, which is where consistent photo tracking becomes valuable.
Age of onset also differs. AA often appears in children and young adults, with the majority of first episodes occurring before age 30. AGA in men typically becomes noticeable in the late 20s to 30s, though it can start earlier. In women, AGA accelerates around perimenopause when estrogen levels decline and the relative influence of androgens increases.
How each condition is diagnosed
A dermatologist can usually distinguish AA from AGA through clinical examination alone. Dermoscopy (a magnified view of the scalp) reveals characteristic features: yellow dots and black dots in AA versus miniaturized hairs of varying diameter in AGA. In ambiguous cases, a scalp biopsy provides a definitive answer by showing either the peribulbar lymphocytic infiltrate of AA or the follicular miniaturization of AGA.
Blood work can support the diagnosis. AA patients may show elevated thyroid antibodies or other autoimmune markers. AGA patients (especially women) may show elevated free testosterone or DHEA-S levels. If you are unsure which type you are dealing with, a visit to a board-certified dermatologist is the fastest path to clarity.
Treatment for alopecia areata
AA treatment targets the immune system, not hormones. The most established approach is intralesional corticosteroid injections, where a dermatologist injects triamcinolone directly into the bald patches every 4-6 weeks. For many patients with limited patches, this produces regrowth within 2-3 months.
The biggest development in AA treatment is the emergence of JAK inhibitors. Baricitinib (Olumiant) received FDA approval for severe AA in 2022, and ritlecitinib (Litfulo) followed in 2023. These oral medications block the Janus kinase signaling pathway that drives the immune attack on follicles. Clinical trials showed significant regrowth in 30-40% of patients with severe AA, a population that previously had very limited options.
Topical immunotherapy (diphencyprone/DPCP) is another option for extensive AA. It works by creating a controlled allergic reaction on the scalp that redirects immune activity away from the follicles. Contact sensitization therapy has response rates of 50-60% but requires regular clinic visits and can cause uncomfortable dermatitis.
One piece of genuinely encouraging data: about 50% of people with limited AA experience spontaneous regrowth within 12 months without any treatment. The follicles are not destroyed, just temporarily suppressed. This is fundamentally different from AGA, where miniaturization is progressive.
Treatment for androgenetic alopecia
AGA treatment focuses on the hormonal pathway. The two FDA-approved medications are minoxidil (topical, available over the counter) and finasteride (oral, prescription). Minoxidil works by increasing blood flow to the follicle and extending the growth phase. Finasteride blocks the enzyme 5-alpha reductase that converts testosterone to DHT, reducing scalp DHT levels by roughly 60-70%.
Dutasteride, a more potent 5-alpha reductase inhibitor, is used off-label for AGA in some countries. Women with AGA may be prescribed spironolactone (an anti-androgen) or topical minoxidil, since finasteride is contraindicated in women of childbearing age. Surgical options like FUE and FUT hair transplants can restore density in areas where follicles are permanently miniaturized.
The critical difference: AGA treatments must be continued indefinitely. Stop finasteride or minoxidil, and the miniaturization process resumes. AA treatments can sometimes be tapered or stopped if the immune attack enters remission.
Can you have both at the same time?
Yes. Having AGA does not protect you from developing AA, and vice versa. This is uncommon, but it does happen, particularly in people with a strong family history of both conditions. The clinical picture can be confusing: gradual thinning in the typical AGA pattern combined with sudden smooth patches. If your hair loss does not fit neatly into one category, a biopsy can sort it out definitively.
Tracking both conditions with photos
Regardless of which condition you have, documented visual evidence is one of the most useful things you can bring to a dermatology appointment. For AA, photos help track patch size, the appearance of regrowth (often white or fine hair initially), and whether new patches are forming. For AGA, photos reveal the gradual density changes that are nearly impossible to detect in real time.
BaldingAI helps standardize this documentation. Consistent lighting, angles, and intervals remove the variables that make casual selfies unreliable for medical assessment. This is especially valuable for distinguishing between hair loss types and for showing your dermatologist objective evidence of how your condition is evolving over weeks and months.
The bottom line: diagnosis dictates treatment
Finasteride will do nothing for alopecia areata. Corticosteroid injections will not stop androgenetic alopecia. The treatments are entirely separate because the underlying mechanisms are entirely separate. One is an immune system problem, the other is a hormone sensitivity problem. Getting the correct diagnosis is not a formality. It is the single most important step in choosing a treatment that actually works.
If you are unsure what type of hair loss you are experiencing, do not guess. Document what you see with consistent photos, note the pattern and speed of loss, and get a professional evaluation. The sooner you have an accurate diagnosis, the sooner you can start the right treatment.
Related reading: when to see a dermatologist and how to start tracking.
